SecBot SecBot

PRPH

ProPhase Labs, Inc.
OTC· Pharmaceutical Preparations· Inc. DE· CIK 0000868278 Biotech & Drug Discovery
$0.010000 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $0.010000
Next earnings
Nov 17
in 21 days
1 year
−99.7%
from $3.80 · Oct 27
30 days
0.0%
from $0.010000
52-week range
$0.010000–3.90
−100% from high · low Sep 16
Avg volume 20D
535.8K
Oct 20 spike 1.64M
Short interest
🔒 Subscribers only
New fund stakes
0
Q3 2025 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 17, 2026
Strongest NEUTRAL Venkatesan Shyam filed a Schedule 13G disclosing a 5.5% passive stake in ProPhase Labs, Inc. (PRPH)…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2025: 2 added (0 new), 3 trimmed or exited.

  • TrendDOWNTREND

    36% below its 50-day average. New closing low $0.010000 on Oct 26.

Who's buying

13F· Q3 2025
0
new positions
0
exits
FundMoveSharesValue
VANGUARD GROUP INCADD531,919$243.6K
SIMPLEX TRADING, LLCDOUBLED40,598$18.0K
UBS Group AGTRIM19,740$9.0K
RENAISSANCE TECHNOLOGIES LLCNEAR_EXIT10,100$4.6K
BANK OF AMERICA CORP /DE/NEAR_EXIT1,118$511.00
RENAISSANCE TECHNOLOGIES LLCTRIM137,923$54.0K
UBS Group AGDOUBLED57,670$22.5K
Cerity Partners LLCNEAR_EXIT19,000$7.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Feb 2024
Recent actions
DateFirmActionRating
Feb 21, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 10, 2023HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 14, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 2, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy
May 12, 2023HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Mar 8, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy

Earnings setup

Estimates
Nov 17
reports in 21 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
PRPH Q3 2026 Earnings Scheduled — 2026-11-17
Recent
Aug 11, 2026
Earnings date
PRPH Q2 2026 Earnings Scheduled — 2026-08-11
May 18, 2026
Earnings date
PRPH Q1 2026 Earnings Scheduled — 2026-05-18
Apr 15, 2026
Earnings date
PRPH Q4 2025 Earnings After Market Close — 2026-04-15
Apr 6, 2026
Earnings date
PRPH Q4 2025 Earnings After Market Close — 2026-04-06
Mar 30, 2026
Earnings date
PRPH Q4 2025 Earnings After Market Close — 2026-03-30

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Venkatesan Shyam filed a Schedule 13G disclosing a 5.5% passive stake in ProPhase Labs, Inc. (PRPH), representing…
SC 13G — Impact 3/10
Aug 11, 2026 Earnings calendar
PRPH Q2 2026 Earnings Scheduled — 2026-08-11
Aug 6, 2026 SEC
ProPhase Labs entered into a senior secured convertible loan agreement with J.J. Astor & Co. for $1.5 million, which…
8-K — Impact 7/10
Jul 9, 2026 SEC
ProPhase Labs filed Amendment No. 2 to its Q1 2026 10-Q, restating previously issued financial statements to correct…
10-Q/A — Impact 8/10
Sep 30, 2025 Inst.
VANGUARD GROUP INC — ADD
531,919 shares ($243.6K)
Sep 30, 2025 Inst.
SIMPLEX TRADING, LLC — DOUBLED
40,598 shares ($18.0K)

SecBot reports

4 filings · 0 bullish · 3 bearish · 1 neutral
All PRPH filing & press-release reports (4)